ALL
The Allstate Corporation
ALL has a slight edge over BAC overall, supported by stronger valuation.
BAC
Bank of America Corporation
BAC has lower modeled downside risk, despite its lower overall score.
ALL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
ALL's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like ALL.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
ALL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 6x | $267 | — |
| Cheap | 6.2x | $274 | +2.6% |
| Forward | 9.1x | $267 | — |
| Fair | 10x | $450 | +69% |
| Expensive | 16x | $726 | +172% |
Historical ranges are pointers, not guarantees.
ALL has the edge over BAC in the historical PE scenario, which offers more potential upside but is not a forecast.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
ALL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Stable | |
| Weakening | |
| Moderate | |
| Low |
Analysts expect ALL's profitability to weaken, with its earnings and revenue holding steady. However, they disagree widely on these estimates.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over ALL on the outlook, with more favorable valuation and earnings expectations.
ALL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $29.22 | -34% |
| Q3 2026 | $44.16 | +43% |
| Q2 2026 | $50.08 | +135% |
| Q1 2026 | $45.33 | +210% |
| Q4 2025 | $38.19 | +125% |
| Q3 2025 | $30.89 | +100% |
| Q2 2025 | $21.27 | +94% |
| Q1 2025 | $14.64 | +223% |
| Q4 2024 | $16.99 | +$18.23 |
ALL's earnings per share have climbed steadily: $44.16 over the past year, up 43% from the year before, and higher year over year for 12 quarters in a row.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
ALL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $17.3B | +0.5% |
| Q2 2026 | $18.6B | +12% |
| Q1 2026 | $16.9B | +3% |
| Q4 2025 | $17.3B | +5.1% |
| Q3 2025 | $17.3B | +3.8% |
| Q2 2025 | $16.6B | +5.8% |
| Q1 2025 | $16.5B | +7.8% |
| Q4 2024 | $16.5B | +11% |
ALL's revenue has grown year over year for 17 quarters in a row: $17.3B last quarter, about level with the same quarter a year ago.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over ALL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
ALL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +15% |
| Q2 2026 | $2.6B | +38% |
| Q1 2026 | $3.5B | +88% |
| Q4 2025 | $2.9B | +75% |
| Q3 2025 | $3.2B | +3.1% |
| Q2 2025 | $1.9B | -19% |
| Q1 2025 | $1.9B | +15% |
| Q4 2024 | $1.7B | +43% |
ALL has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
ALL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -3.8M shares |
| 1 year | -4.2% | -11.1M shares |
| 3 years | -2.5% | -6.5M shares |
| 5 years | -14% | -42.6M shares |
| Available history | -23% | -78.2M shares |
ALL has 255M diluted shares, down 4.2% from a year ago, with $3.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.1B |
| Q1 2026 | $614M |
| Q4 2025 | $434M |
| Q3 2025 | $360M |
| Q2 2025 | $340M |
| Q1 2025 | $99M |
| Q4 2024 | $2M |
ALL spent $3.3B buying back its own shares over the past year, about four times what it spent the year before.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over ALL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
ALL Net Leverage
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
ALL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.7 | Neutral |
| Stochastic | 67.9 | Neutral |
ALL's weekly RSI is 63 (neutral) and its Stochastic is 68 (neutral).
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
ALL PE vs Financial Services Sector
| Metric | ALL | Sector median | Relative |
|---|---|---|---|
| PE | 6x | 13x | 54% below |
| PE % | 15 | 63 | 48 pts below |
ALL has the edge over BAC on valuation relative to its sector.
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
ALL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $245.4 | 8.7% above |
| 20 week MA | $252.3 | 5.7% above |
| 50 week MA | $227.0 | 17% above |
| 100 week MA | $213.2 | 25% above |
| 200 week MA | $179.8 | 48% above |
ALL has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
ALL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $111.9 | $107.2 | -4.2% |
| 2021 | $107.2 | $114.1 | +6.5% |
| 2022 | $114.1 | $136.4 | +19% |
| 2023 | $136.4 | $140.0 | +2.6% |
| 2024 | $140.0 | $193.8 | +38% |
| 2025 | $193.8 | $207.8 | +7.2% |
| 2026 YTD | $207.8 | $266.7 | +28% |
ALL has the edge over BAC on returns for 2026, with the stronger performance.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.